Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis
Author:
Funder
Novartis Pharmaceuticals Corporation
Novartis
Publisher
Elsevier BV
Subject
Ophthalmology,General Medicine
Reference35 articles.
1. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements;Mantel;Transl Vis Sci Technol,2015
2. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration (nAMD);Mantel;Surv Ophthalmol,2018
3. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis;Spooner;Clin Ophthalmol,2017
4. Recent developments in age-related macular degeneration: a review;Al-Zamil;Clin Interv Aging,2017
5. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort;Gillies;Ophthalmology,2014
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab;Ophthalmology and Therapy;2024-08-30
2. Clinical Characteristics of Unilateral Macular Neovascularization Patients with Pachydrusen in the Fellow Eye;Journal of Clinical Medicine;2024-06-27
3. Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice;Ophthalmology Science;2024-05
4. Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration;Ophthalmology Science;2024-03
5. The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD;Journal of Ophthalmology;2024-01-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3